Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 286, doi. 10.1007/s11899-019-00523-x
- By:
- Publication type:
- Article
Works matching IS 15588211 AND DT 2019 AND VI 14 AND IP 4
Results: 15
1
2
Targeting Translation of mRNA as a Therapeutic Strategy in Cancer.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 219, doi. 10.1007/s11899-019-00530-y
- By:
- Publication type:
- Article
3
Overcoming Challenges in Process Development of Cellular Therapies.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 269, doi. 10.1007/s11899-019-00529-5
- By:
- Publication type:
- Article
4
Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 261, doi. 10.1007/s11899-019-00528-6
- By:
- Publication type:
- Article
5
Towards Automated Manufacturing for Cell Therapies.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 278, doi. 10.1007/s11899-019-00522-y
- By:
- Publication type:
- Article
6
Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 247, doi. 10.1007/s11899-019-00521-z
- By:
- Publication type:
- Article
7
The Rationale for Immunotherapy in Myeloproliferative Neoplasms.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 310, doi. 10.1007/s11899-019-00527-7
- By:
- Publication type:
- Article
8
Emerging Role of Integrative Medicine in Hematologic Malignancies: a Literature Review and Update on Current Trends in Complementary Medical Practices in Hematologic Cancers.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 328, doi. 10.1007/s11899-019-00526-8
- By:
- Publication type:
- Article
9
Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 292, doi. 10.1007/s11899-019-00525-9
- By:
- Publication type:
- Article
10
Is There a Role for Dose Modification of TKI Therapy in CML?
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 337, doi. 10.1007/s11899-019-00524-w
- By:
- Publication type:
- Article
11
Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 302, doi. 10.1007/s11899-019-00511-1
- By:
- Publication type:
- Article
12
Mantle Cell Lymphoma: Which Patients Should We Transplant?
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 239, doi. 10.1007/s11899-019-00520-0
- By:
- Publication type:
- Article
13
Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 228, doi. 10.1007/s11899-019-00519-7
- By:
- Publication type:
- Article
14
Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 207, doi. 10.1007/s11899-019-00518-8
- By:
- Publication type:
- Article
15
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 4, p. 346, doi. 10.1007/s11899-019-00517-9
- By:
- Publication type:
- Article